Most of the retatrutide conversation so far has been about the scale on the bathroom floor — and for good reason, since Lilly’s triple agonist has posted the largest weight-loss numbers of any GLP-1-class drug in development. But the most clinically interesting data to come out of the TRIUMPH Phase 3 program isn’t a weight number at all. It’s what happened to knee pain. In TRIUMPH-4, a dedicated trial in people with obesity and knee osteoarthritis, retatrutide didn’t just help patients lose weight — it left more than one in eight of them completely free of knee pain by the end of the trial. As Lilly prepares to file this data with the FDA later in 2026, it’s worth separating the joint-health story from the weight-loss headline it’s usually buried under.
A Trial Built Specifically for This Question
TRIUMPH-4 wasn’t a weight-loss trial that happened to track joint pain as an afterthought — it was purpose-built to test retatrutide specifically in people with obesity or overweight and clinically and radiologically confirmed knee osteoarthritis, using American College of Rheumatology diagnostic criteria. The Phase 3, 68-week, placebo-controlled trial randomized 445 participants without diabetes to retatrutide 9 mg, 12 mg, or placebo, with roughly 84% of participants starting with a BMI of 35 or higher. Announced in December 2025, it was the first of the TRIUMPH program’s four registrational trials to report positive topline results, and both retatrutide doses hit every primary and key secondary endpoint.
What the Data Actually Showed
On the weight side, participants on the 12 mg dose lost an average of 28.7% of body weight — about 71.2 pounds — against a modest 2.1% loss on placebo, among those who stayed on treatment through 68 weeks. That’s consistent with retatrutide’s now-familiar pattern of outperforming other GLP-1-class drugs on raw weight-loss percentage.
The pain data is where TRIUMPH-4 earns its own headline. Using the WOMAC pain subscale — a validated, patient-reported osteoarthritis pain and function questionnaire scored 0 to 10 — retatrutide reduced pain scores by an average of 4.5 points, a 75.8% reduction, more than double the roughly 40% improvement seen on placebo. Physical function scores improved by a similar margin, down 71.8% on the 9 mg dose. Perhaps the most striking single number: in a post-hoc analysis, 14.1% of patients on the 9 mg dose and 12.0% on the 12 mg dose reported being completely free of knee pain at 68 weeks, compared to 4.2% on placebo. For a chronic, progressive condition that currently has no disease-modifying drug treatment — only pain management and, eventually, joint replacement — a meaningful share of patients reporting zero pain is a genuinely unusual result in an osteoarthritis trial.
Retatrutide also moved several cardiovascular risk markers in the right direction, including reductions in non-HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein, and lowered systolic blood pressure by 14.0 mmHg at the highest dose — a reminder that the drug’s downstream effects extend well past weight and joints.
Weight Loss or Direct Joint Effect?
The obvious question TRIUMPH-4 raises — and one the topline data alone can’t fully answer — is how much of the pain relief is simply the mechanical benefit of carrying less weight on an arthritic knee, versus a more direct anti-inflammatory or metabolic effect of the drug itself. Obesity is a well-established driver of knee osteoarthritis progression, both mechanically (more load on the joint) and metabolically (adipose tissue drives systemic inflammation that worsens joint damage). A 28.7% body weight reduction alone would be expected to meaningfully reduce joint loading. Untangling how much of the 75.8% pain reduction is downstream of weight loss versus a more direct pharmacological effect on inflammation is exactly the kind of question the full peer-reviewed publication — still pending — should help clarify.
Kenneth Custer, Ph.D., executive vice president and president of Lilly Cardiometabolic Health, framed the results as evidence of a first-in-class effect, describing “the powerful effect of retatrutide” on “body weight, pain and physical function” and noting that with seven additional Phase 3 readouts expected across 2026, the company sees knee osteoarthritis as one of several serious weight-related complications retatrutide could eventually be approved to treat.
The Trade-Offs
TRIUMPH-4’s side-effect profile tracked the rest of the GLP-1 class, with nausea (up to 43.2%), diarrhea, constipation, vomiting, and decreased appetite all more common on retatrutide than placebo. One notable standout: dysesthesia — abnormal skin sensations — occurred in 20.9% of patients on the 12 mg dose versus just 0.7% on placebo, echoing the same side effect that showed up prominently in Wegovy HD’s STEP UP trial data. Discontinuation due to adverse events was also meaningfully higher on retatrutide (up to 18.2%) than placebo (4.0%), with the company noting some of those discontinuations were driven by “perceived excessive weight loss” — an unusual problem to have, but a real one in a trial population that started with an average BMI over 40.
What Happens Next
Detailed TRIUMPH-4 results are still pending presentation at a medical meeting and publication in a peer-reviewed journal — the topline numbers here come from Lilly’s own December 2025 announcement, not an independently reviewed paper. Lilly has indicated it plans to submit the full TRIUMPH program data to the FDA, including the knee osteoarthritis indication, later in 2026, with the earliest possible approval decision not expected before mid-2027. Six of the eleven total TRIUMPH Phase 3 trials had reported by the time TRIUMPH-4 posted its results, with more readouts — covering obstructive sleep apnea, type 2 diabetes, and other indications — still to come across 2026.
Frequently Asked Questions
Is retatrutide approved for osteoarthritis?
No. Retatrutide remains investigational and is not yet approved for any indication. Lilly plans to file the TRIUMPH-4 osteoarthritis data with the FDA later in 2026, with a decision not expected before mid-2027 at the earliest.
How is this different from your other retatrutide coverage?
Our deep dive into retatrutide’s triple-agonist mechanism covers the drug’s overall weight-loss data and how it compares to tirzepatide and semaglutide. This article focuses specifically on the TRIUMPH-4 osteoarthritis trial and what the joint-pain data shows on its own terms.
Does this mean GLP-1 drugs treat arthritis directly?
Not established yet. The trial can’t fully separate how much benefit comes from weight loss reducing joint load versus a more direct anti-inflammatory effect. That distinction matters for understanding the drug’s actual mechanism and will likely be addressed in the full peer-reviewed publication.
How does retatrutide’s pain data compare to other GLP-1s?
TRIUMPH-4 is the first dedicated Phase 3 osteoarthritis trial for any GLP-1-class drug to report this kind of data, so direct comparisons to Wegovy or Zepbound in this specific indication aren’t yet available. See our coverage of Wegovy HD’s STEP UP trial results for how the broader weight-loss class compares on efficacy generally.
The Bigger Picture
If the TRIUMPH-4 findings hold up through peer review and FDA review, retatrutide would be positioned as something genuinely new: a drug that treats both the metabolic driver and a serious downstream complication of obesity in a single prescription, for a condition — knee osteoarthritis — that currently has no approved disease-modifying treatment at all. That’s a meaningfully bigger claim than “another weight-loss drug,” and it’s why this specific trial, more than the topline weight numbers alone, may end up being the more consequential result from the TRIUMPH program.
This article is for educational purposes only and summarizes topline results from a Phase 3 clinical trial announced by the manufacturer. Retatrutide is investigational and not yet FDA-approved. It is not medical advice.